These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 35088054)

  • 1. Structural Analysis of the SARS-CoV-2 Omicron Variant Proteins.
    Yang Q; Syed AAS; Fahira A; Shi Y
    Research (Wash D C); 2021; 2021():9769586. PubMed ID: 35088054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural models of SARS-CoV-2 Omicron variant in complex with ACE2 receptor or antibodies suggest altered binding interfaces.
    Lubin JH; Markosian C; Balamurugan D; Pasqualini R; Arap W; Burley SK; Khare SD
    bioRxiv; 2021 Dec; ():. PubMed ID: 34931193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epistasis at the SARS-CoV-2 RBD Interface and the Propitiously Boring Implications for Vaccine Escape.
    Rochman ND; Faure G; Wolf YI; Freddolino PL; Zhang F; Koonin EV
    bioRxiv; 2021 Dec; ():. PubMed ID: 34494024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift.
    Cameroni E; Saliba C; Bowen JE; Rosen LE; Culap K; Pinto D; VanBlargan LA; De Marco A; Zepeda SK; Iulio JD; Zatta F; Kaiser H; Noack J; Farhat N; Czudnochowski N; Havenar-Daughton C; Sprouse KR; Dillen JR; Powell AE; Chen A; Maher C; Yin L; Sun D; Soriaga L; Bassi J; Silacci-Fregni C; Gustafsson C; Franko NM; Logue J; Iqbal NT; Mazzitelli I; Geffner J; Grifantini R; Chu H; Gori A; Riva A; Giannini O; Ceschi A; Ferrari P; Cippà P; Franzetti-Pellanda A; Garzoni C; Halfmann PJ; Kawaoka Y; Hebner C; Purcell LA; Piccoli L; Pizzuto MS; Walls AC; Diamond MS; Telenti A; Virgin HW; Lanzavecchia A; Veesler D; Snell G; Corti D
    bioRxiv; 2021 Dec; ():. PubMed ID: 34931194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Omicron Variant (B.1.1.529): Infectivity, Vaccine Breakthrough, and Antibody Resistance.
    Chen J; Wang R; Gilby NB; Wei GW
    J Chem Inf Model; 2022 Jan; 62(2):412-422. PubMed ID: 34989238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinct core glycan and
    Roberts DS; Mann M; Li BH; Kim D; Braiser AR; Jin S; Ge Y
    Chem Sci; 2022 Sep; 13(36):10944-10949. PubMed ID: 36320702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural Comparison and Drug Screening of Spike Proteins of Ten SARS-CoV-2 Variants.
    Yang Q; Jian X; Syed AAS; Fahira A; Zheng C; Zhu Z; Wang K; Zhang J; Wen Y; Li Z; Pan D; Lu T; Wang Z; Shi Y
    Research (Wash D C); 2022; 2022():9781758. PubMed ID: 35198984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural analysis of spike proteins from SARS-CoV-2 variants of concern highlighting their functional alterations.
    Solanki K; Rajpoot S; Kumar A; J Zhang KY; Ohishi T; Hirani N; Wadhonkar K; Patidar P; Pan Q; Baig MS
    Future Virol; 2022 Jul; ():. PubMed ID: 35935449
    [No Abstract]   [Full Text] [Related]  

  • 9. Distinct Core Glycan and O-Glycoform Utilization of SARS-CoV-2 Omicron Variant Spike Protein RBD Revealed by Top-Down Mass Spectrometry.
    Roberts DS; Mann M; Li BH; Kim D; Brasier AR; Jin S; Ge Y
    bioRxiv; 2022 Apr; ():. PubMed ID: 35475171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Omicron Variant of SARS-CoV-2 Virus:
    Bassani D; Ragazzi E; Lapolla A; Sartore G; Moro S
    Front Endocrinol (Lausanne); 2022; 13():847993. PubMed ID: 35321335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SARS-CoV-2 Omicron variant: Immune escape and vaccine development.
    Ao D; Lan T; He X; Liu J; Chen L; Baptista-Hon DT; Zhang K; Wei X
    MedComm (2020); 2022 Mar; 3(1):e126. PubMed ID: 35317190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Omicron SARS-CoV-2 Variant Spike Protein Shows an Increased Affinity to the Human ACE2 Receptor: An In Silico Analysis.
    Ortega JT; Jastrzebska B; Rangel HR
    Pathogens; 2021 Dec; 11(1):. PubMed ID: 35055993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Minimal cross-over between mutations associated with Omicron variant of SARS-CoV-2 and CD8+ T cell epitopes identified in COVID-19 convalescent individuals.
    Redd AD; Nardin A; Kared H; Bloch EM; Abel B; Pekosz A; Laeyendecker O; Fehlings M; Quinn TC; Tobian AA
    bioRxiv; 2021 Dec; ():. PubMed ID: 34909772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Omicron (B.1.1.529): Infectivity, vaccine breakthrough, and antibody resistance.
    Chen J; Wang R; Gilby NB; Wei GW
    ArXiv; 2021 Dec; ():. PubMed ID: 34873578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SARS-CoV-2 Omicron Mutation Is Faster than the Chase: Multiple Mutations on Spike/ACE2 Interaction Residues.
    Kim S; Nguyen TT; Taitt AS; Jhun H; Park HY; Kim SH; Kim YG; Song EY; Lee Y; Yum H; Shin KC; Choi YK; Song CS; Yeom SC; Kim B; Netea M; Kim S
    Immune Netw; 2021 Dec; 21(6):e38. PubMed ID: 35036025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential escape of neutralizing antibodies by SARS-CoV-2 Omicron and pre-emergent sarbecoviruses.
    Wang LF; Tan CW; Chia WN; Zhu F; Young B; Chantasrisawad N; Hwa SH; Yeoh AY; Lim BL; Yap WC; Pada SK; Tan SY; Jantarabenjakul W; Chen S; Zhang J; Mah YY; Chen V; Chen M; Wacharapluesadee S; ; Putcharoen O; Lye D
    Res Sq; 2022 Feb; ():. PubMed ID: 35233568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of SARS-CoV-2 Omicron Variant Immunogenicity, Immune Escape and Pathogenicity, through the Analysis of Spike Protein-Specific Core Unique Peptides.
    Kontopodis E; Pierros V; Stravopodis DJ; Tsangaris GT
    Vaccines (Basel); 2022 Feb; 10(3):. PubMed ID: 35334990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutational Pattern, Impacts and Potential Preventive Strategies of Omicron SARS-CoV-2 Variant Infection.
    Chekol Abebe E; Tiruneh G/Medhin M; Behaile T/Mariam A; Asmamaw Dejenie T; Mengie Ayele T; Tadele Admasu F; Tilahun Muche Z; Asmare Adela G
    Infect Drug Resist; 2022; 15():1871-1887. PubMed ID: 35450114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccines Elicit Highly Cross-Reactive Cellular Immunity to the SARS-CoV-2 Omicron Variant.
    Liu J; Chandrashekar A; Sellers D; Barrett J; Lifton M; McMahan K; Sciacca M; VanWyk H; Wu C; Yu J; Collier AY; Barouch DH
    medRxiv; 2022 Jan; ():. PubMed ID: 35018387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the RBD of Omicron Variant (B.1.1.529) with Medicinal Phytocompounds to Abrogate the Binding of Spike Glycoprotein with the hACE2 Using Computational Molecular Search and Simulation Approach.
    Hakami AR
    Biology (Basel); 2022 Feb; 11(2):. PubMed ID: 35205124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.